• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Gilead's HCV combination has better efficacy than AbbVie's









You work at gilead op

I would have gone for different approach to introduce Gilead’s HCV regimen if I worked at Gilead OP. HCV is a multibillion dollar sale business. The competition is intense, even evidenced in this anonymous forum. Gilead is trying to catch up the sales with its new regimen, while they need to develop better sale strategies for the competition. We will see.